Aleksandr Lazaryan
Overview
Explore the profile of Aleksandr Lazaryan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
1886
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mehta R, Choe H, Saultz J, Gong Z, Sharma P, Al-Juhaishi T, et al.
Am J Hematol
. 2025 Mar;
PMID: 40071498
Cytomegalovirus (CMV) infection post-hematopoietic cell transplantation (HCT) remains a significant cause of morbidity and mortality. While letermovir prophylaxis is available for CMV-seropositive recipients, optimal donor selection for CMV-seronegative recipients remains...
2.
Mammadova J, Glass L, LaFave D, Pidala J, Lazaryan A
JAAD Case Rep
. 2025 Feb;
57:22-24.
PMID: 39936157
No abstract available.
3.
Adoncecchi G, Kumar A, Mogili K, Faramand R, Liu H, Khimani F, et al.
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39858092
Background: Previous studies have shown that allogeneic peripheral blood stem cell transplantation (PBSCT) from an HLA haploidentical (haplo) donor followed by graft-versus-host disease (GVHD) prophylaxis with post-transplant cyclophosphamide (PTCy) results...
4.
Handley G, Yepes A, Eliassen E, Dominguez G, Pasikhova Y, Klinkova O, et al.
Open Forum Infect Dis
. 2024 Oct;
11(10):ofae564.
PMID: 39411216
Background: Human herpesvirus 6B (HHV-6B) frequently reactivates following allogeneic stem cell transplant (alloHCT). Consensus guidelines note that haploidentical alloHCT may represent a high-risk population for which there is little evidence;...
5.
Hoogland A, Barata A, Li X, Irizarry-Arroyo N, Jain M, Welniak T, et al.
Transplant Cell Ther
. 2024 Sep;
30(12):1219.e1-1219.e11.
PMID: 39306278
Chimeric antigen receptor (CAR) T-cell therapy has transformed survival outcomes in patients with relapsed and refractory large B-cell lymphoma (LBCL), but it is associated with a variety of side effects....
6.
Elmariah H, Otoukesh S, Kumar A, Ali H, Arslan S, Dimaggio E, et al.
Transplant Cell Ther
. 2024 Aug;
30(10):1019.e1-1019.e9.
PMID: 39102983
Mycophenolate mofetil (MMF) is commonly included in post-transplant cyclophosphamide (PTCy) based graft-versus-host disease (GVHD) prophylaxis after haploidentical (haplo) hematopoietic cell transplant (HCT). In the non-PTCy setting, higher MMF dose/kg has...
7.
Mohty R, Lazaryan A
Front Oncol
. 2024 Jul;
14:1433432.
PMID: 39055556
Chimeric antigen receptor T-cell therapy (CAR T) has revolutionized the treatment landscape for hematologic malignancies, notably B-cell non-Hodgkin lymphoma (B-NHL) and B-cell acute lymphoblastic leukemia (B-ALL). While autologous CAR T...
8.
Shadman M, Ahn K, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, et al.
Blood Cancer J
. 2024 Jul;
14(1):108.
PMID: 38977682
In patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality provides superior outcomes. We...
9.
Zhang Y, Rose A, Khadka S, Cao B, Eatrides J, Saeed H, et al.
Transplant Cell Ther
. 2024 May;
30(9):887.e1-887.e9.
PMID: 38740140
Nodal peripheral T cell lymphomas (PTCLs) are challenging subsets of non-Hodgkin lymphomas characterized by their heterogeneity and aggressive clinical behavior. Given the mixed outcomes reported in previous studies, the efficacy...
10.
Caprice T, Fan W, Kim J, Faramand R, Mishra A, Perez L, et al.
Am J Hematol
. 2024 Mar;
99(6):1196-1200.
PMID: 38546371
No abstract available.